Business Context and Reporting Period
This Form 6-K filing by Legend Biotech Corporation, dated August 18, 2025, announces a significant executive leadership change. The report details the appointment of Carlos Santos as Chief Financial Officer (CFO), effective August 18, 2025. Mr. Santos succeeds Jessie Yeung, who served as interim CFO since January 2025. The filing also discloses the terms of Mr. Santos' employment agreement.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: $500,000 annually.
- Target Annual Cash Bonus: 45% of base salary.
- Target Annual Equity Grant (RSUs): Anticipated fair market value of at least $1 million, commencing in fiscal year 2026.
Material Changes
The primary material change is the transition of the CFO role from an interim basis to a permanent appointment with Carlos Santos. This change introduces new compensation structures and severance obligations for the company, replacing the interim arrangements in place since January 2025.
Outlook, Risks, and Contingencies
Employment Terms and Severance: The employment agreement outlines significant contingent liabilities based on termination scenarios:
- Termination without Cause/Good Reason (No Change in Control): Entitles Mr. Santos to 12 months of base salary, pro-rated bonus, prior year bonus, 12 months of COBRA coverage, and acceleration of equity awards vesting over the subsequent 12-month period (subject to corporate performance goals).
- Termination without Cause/Good Reason (Change in Control): Entitles Mr. Santos to 18 months of base salary, full target bonus for the year, prior year bonus, 18 months of COBRA coverage, and full acceleration of all unvested equity awards.
- Termination for Cause/Resignation without Good Reason: No severance benefits are payable.
Risks: The company faces potential cash outflows and equity dilution if Mr. Santos' employment is terminated under the specified severance conditions. The actual equity grant amounts are subject to determination by the Compensation Committee.
Investor Verification Checklist
- Verify the total potential cash and equity liability exposure under the Change in Control severance provisions.
- Confirm the specific corporate performance metrics required for the acceleration of equity awards in non-Change in Control scenarios.
- Review the full text of the Employment Agreement (to be filed in the 2025 Form 20-F) for complete terms and conditions.
- Assess the impact of the $1 million+ annual equity grant target on future share dilution starting in fiscal year 2026.